Immune checkpoint blockade therapies, such as anti-programmed death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have provided new hope for the treatment of hematological malignancies [9]. This evidence concerns the gene CTLA4 and hematologic disorder.